Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07291323 | Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. | EARLY_PHASE1 | RECRUITING | 60 | — | — | Feb 16, 2026 | Dec 1, 2026 | Apr 23, 2026 | 1 | Australia |
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Dosage per cohort will increase to determine the maximum tolerable dose. |
| Name | Type | Description |
|---|---|---|
| JANX011 | DRUG | JANX011 is administered subcutaneously, one time. |
Inclusion Criteria: * Healthy men and women, in the opinion of the PI or designee and as determined by physical examination, laboratory screening tests, and medical history. * Aged 18 to 65 years, with a body weight between 50 to 120 kg and a body mass index (BMI) between 18 to 32 kg/m2 (all inclus...